Posted by Michael Wonder on 12 Oct 2020
SMC - October 2020 decisions
12 October 2020 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today published advice on nine new medicines.
An initial Assessment Report has been published for cerliponase alfa (Brineura) for the treatment of neuronal ceroid lipofuscinosis type 2, a life limiting, inherited condition in children that leads to progressive brain damage.
Ibrutinib (Imbruvica) was accepted for the treatment of Waldenstrom's macroglobulinaemia in combination with another medicine, rituximab.
